Best Practice & Research Clinical Haematology
Volume 22, Issue 1 , Pages 71-83 , March 2009

Tissue factor in tumour progression

  • Janusz Rak, MD, PhD, Doctor

      Affiliations

    • Montreal Children's Hospital Research Institute, 4060 Ste Catherine West, Montreal, QC, H3Z 3Z2, Canada
    • Corresponding Author InformationCorresponding author. Tel.: +1 514 412 4400x22342; Fax: +1 514 412 4331.
    • ,
  • Chloe Milsom, BSc

      Affiliations

    • Henderson Research Centre, McMaster University, Hamilton, ON, Canada
    • ,
  • Nathalie Magnus, BSc

      Affiliations

    • Montreal Children's Hospital, McGill University, QC, Canada
    • ,
  • Joanne Yu, MD, PhD, Doctor

      Affiliations

    • University of Toronto, Toronto, ON, Canada

References 

  1. Folkman J, Kalluri R. Tumor angiogenesis. In:  Kufe DW,  Pollock RE,  Weichselbaum RR editor. Cancer medicine. Hamilton, London: BC Decker Inc; 2003;p. 161–194
  2. Rak J, Kerbel RS. Oncogenes and tumor angiogenesis. In:  Rak J editors. Oncogene-directed therapies. Totowa: Humana Press; 2003;p. 171–218
  3. Tehrani M, Friedman TM, Olson JJ, et al. Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma. Brain Pathol. 2008;18:164–171
  4. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039–2049
  5. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79:315–328
  6. Italiano JE, Richardson JL, Patel-Hett S, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood. 2008;111:1227–1233
  7. Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105:1734–1741
  8. Dolo V, D'Ascenzo S, Giusti I, et al. Shedding of membrane vesicles by tumor and endothelial cells. Ital J Anat Embryol. 2005;110:127–133
  9. Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, et al. Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother. 2006;55:808–818
  10. Gesierich S, Berezovskiy I, Ryschich E, et al. Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029. Cancer Res. 2006;66:7083–7094
  11. Rafii S, Lyden D, Benezra R, et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat Rev Cancer. 2002;2:826–835
  12. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7:575–583
  13. Shojaei F, Singh M, Thompson JD, et al. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci USA. 2008;105:2640–2645
  14. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964–967
  15. Rak J, Filmus J, Kerbel RS. Reciprocal paracrine interactions between tumor cells and endothelial cells. The “angiogenesis progression” hypothesis. Eur J Cancer. 1996;32A:2438–2450
  16. Skobe M, Rockwell P, Goldstein N, et al. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med. 1997;3:1222–1227
  17. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 1998;4:923–928
  18. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400
  19. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  20. Fernando NH, Hurwitz HI. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist. 2004;9(Suppl. 1):11–18
  21. Sandler A, Herbst R. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res. 2006;12:4421–4425
  22. Pettersson A, Nagy JA, Brown LF, et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest. 2000;80:99–115
  23. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med. 2003;9:713–725
  24. St. Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science. 2000;289:1197–1202
  25. Dvorak FH, Rickles FR. Malignancy and hemostasis. In:  Coleman RB,  Marder VJ,  Clowes AW,  George JN,  Goldhaber SZ editor. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: Lippincott Company Williams & Wilkins; 2006;p. 851–873
  26. Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb. 2006;35:103–110
  27. Klement H, St CB, Milsom C, et al. Atherosclerosis and vascular aging as modifiers of tumor progression, angiogenesis, and responsiveness to therapy. Am J Pathol. 2007;171:1342–1351
  28. Falanga A, Barbui T, Rickles FR. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost. 2008;34:204–210
  29. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318:404–407
  30. Zacharski LR. Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancer. Semin Thromb Hemost. 2003;29:239–246
  31. Buller HR, van Doormaal FF, van Sluis GL, et al. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost. 2007;5(Suppl. 1):246–254
  32. Tesselaar ME, Romijn FP, Van Der Linden IK, et al. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost. 2007;5:520–527
  33. Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol. 2007;62:126–136
  34. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost. 2005;31:104–110
  35. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest. 2003;124:58S–68
  36. Petralia GA, Lemoine NR, Kakkar AK. Mechanisms of disease: the impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol. 2005;2:356–363
  37. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23:2123–2129
  38. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22:1944–1948
  39. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004;2:1266–1271
  40. Rak J, Yu JL, Luyendyk J, et al. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res. 2006;66:10643–10646
  41. Kuenen BC, Levi M, Meijers JC, et al. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol. 2002;22:1500–1505
  42. Boccaccio C, Sabatino G, Medico E, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature. 2005;434:396–400
  43. Tallman MS, Lefebvre P, Baine RM, et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost. 2004;2:1341–1350
  44. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol. 2004;24:1015–1022
  45. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258–264
  46. Ruf W. Redundant signaling of tissue factor and thrombin in cancer progression?. J Thromb Haemost. 2007;5:1584–1587
  47. Mackman N. Tissue-specific hemostasis in mice. Arterioscler Thromb Vasc Biol. 2005;25:2273–2281
  48. Milsom C, Yu J, May L, et al. Diverse roles of tissue factor-expressing cells in tumor progression. Semin Thromb Hemost. 2008;34:170–181
  49. Contrino J, Hair G, Kreutzer DL, et al. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 1996;2:209–215
  50. Rak J, Milsom C, Yu J. Tissue factor in cancer. Curr Opin Hematol. 2008;15:522–528
  51. Croce CM. Oncogenes and cancer. N Engl J Med. 2008;358:502–511
  52. Rak J, Klement G. Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer. Cancer Metastasis Rev. 2000;19:93–96
  53. Rong Y, Post DE, Pieper RO, et al. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 2005;65:1406–1413
  54. Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost. 2004;2:2065–2067
  55. Yu J, May L, Milsom C, et al. Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol. 2008;28:1975–1981
  56. Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008;10:619–624
  57. Bogdanov VY, Balasubramanian V, Hathcock J, et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med. 2003;9:458–462
  58. Hobbs JE, Zakarija A, Cundiff DL, et al. Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res. 2007;120(Suppl. 2):S13–S21
  59. Chand HS, Ness SA, Kisiel W. Identification of a novel human tissue factor splice variant that is upregulated in tumor cells. Int J Cancer. 2006;118:1713–1720
  60. Szotowski B, Antoniak S, Rauch U. Alternatively spliced tissue factor: a previously unknown piece in the puzzle of hemostasis. Trends Cardiovasc Med. 2006;16:177–182
  61. Mackman N. Alternatively spliced tissue factor – one cut too many?. Thromb Haemost. 2007;97:5–8
  62. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003;15:740–746
  63. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111
  64. Palumbo JS, Talmage KE, Massari JV, et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood. 2007;110:133–141
  65. Francis JL, Amirkhosravi A. Effect of antihemostatic agents on experimental tumor dissemination. Semin Thromb Hemost. 2002;28:29–38
  66. Mueller BM, Reisfeld RA, Edgington TS, et al. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA. 1992;89:11832–11836
  67. Milsom C, Yu J, Mackman N, et al. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res. 2008;68:10068–10076
  68. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–715
  69. Milsom C, Anderson GM, Weitz JI, et al. Elevated tissue factor procoagulant activity in CD133-positive cancer cells. J Thromb Haemost. 2007;5:2550–2552
  70. Vrana JA, Stang MT, Grande JP, et al. Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family. Cancer Res. 1996;56:5063–5070
  71. Lwaleed BA, Bass PS, Cooper AJ. The biology and tumour-related properties of monocyte tissue factor. J Pathol. 2001;193:3–12
  72. Belting M, Dorrell MI, Sandgren S, et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med. 2004;10:502–509
  73. Ngo CV, Manning CA, McCabe F, et al. Combination antibody therapy targeting both xenograft- and host-derived tissue factor leads to potent tumor inhibition. Proc Am Assoc Cancer Res. 2005;46:
  74. Mechtcheriakova D, Wlachos A, Holzmuller H, et al. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood. 1999;93:3811–3823
  75. Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 1994;94:1320–1327
  76. Hembrough TA, Swartz GM, Papathanassiu A, et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res. 2003;63:2997–3000
  77. Abe K, Shoji M, Chen J, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci U S A. 1999;96:8663–8668
  78. Bromberg ME, Sundaram R, Homer RJ, et al. Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost. 1999;82:88–92
  79. Ngo CV, Picha K, McCabe F, et al. CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models. Int J Cancer. 2007;120:1261–1267
  80. Versteeg HH, Schaffner F, Kerver M, et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood. 2008;111:190–199
  81. Wang X, Wang M, Amarzguioui M, et al. Downregulation of tissue factor by RNA interference in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice. Int J Cancer. 2004;112:994–1002
  82. Hu Z, Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci U S A. 2001;98:12180–12185
  83. Toomey JR, Kratzer KE, Lasky NM, et al. Effect of tissue factor deficiency on mouse and tumor development. Proc Natl Acad Sci USA. 1997;94:6922–6926
  84. Lazarus RA, Olivero AG, Eigenbrot C, et al. Inhibitors of tissue factor. Factor VIIa for anticoagulant therapy. Curr Med Chem. 2004;11:2275–2290
  85. Viloria-Petit A, Miquerol L, Yu JL, et al. Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J. 2003;22:4091–4102
  86. Koizume S, Jin MS, Miyagi E, et al. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res. 2006;66:9453–9460
  87. Huang X, Molema G, King S, et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 1997;275:547–550
  88. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23:2130–2135
  89. Lwaleed BA, Francis JL, Chisholm M. Urinary tissue factor levels in patients with bladder and prostate cancer. Eur J Surg Oncol. 2000;26:44–49
  90. Forster Y, Meye A, Albrecht S, et al. Tissue specific expression and serum levels of human tissue factor in patients with urological cancer. Cancer Lett. 2003;193:65–73
  91. Patry G, Hovington H, Larue H, et al. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer. Int J Cancer. 2008;122:1592–1597
  92. Takano S, Tsuboi K, Tomono Y, et al. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer. 2000;82:1967–1973
  93. Takeshima H, Nishi T, Kuratsu J, et al. Suppression of the tissue factor-dependent coagulation cascade: a contributing factor for the development of intratumoral hemorrhage in glioblastoma. Int J Mol Med. 2000;6:271–276
  94. Hamada K, Kuratsu J, Saitoh Y, et al. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer. 1996;77:1877–1883
  95. Guan M, Jin J, Su B, et al. Tissue factor expression and angiogenesis in human glioma. Clin Biochem. 2002;35:321–325
  96. Brat DJ, Van Meir EG. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest. 2004;84:397–405
  97. Hron G, Kollars M, Weber H, et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost. 2007;97:119–123
  98. Altomare DF, Rotelli MT, Memeo V, et al. Expression of tissue factor and vascular endothelial growth factor in colorectal carcinoma, Tumori. 2003;89:5–6
  99. Nakasaki T, Wada H, Shigemori C, et al. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol. 2002;69:247–254
  100. Seto S, Onodera H, Kaido T, et al. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer. 2000;88:295–301
  101. Shigemori C, Wada H, Matsumoto K, et al. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost. 1998;80:894–898
  102. Kataoka H, Uchino H, Asada Y, et al. Analysis of tissue factor and tissue factor pathway inhibitor expression in human colorectal carcinoma cell lines and metastatic sublines to the liver. Int J Cancer. 1997;72:878–884
  103. Szczepanski M, Bardadin K, Zawadzki J, et al. Procoagulant activity of gastric, colorectal, and renal cancer is factor VII-dependent. J Cancer Res Clin Oncol. 1988;114:519–522
  104. Yamashita H, Kitayama J, Ishikawa M, et al. Tissue factor expression is a clinical indicator of lymphatic metastasis and poor prognosis in gastric cancer with intestinal phenotype. J Surg Oncol. 2007;95:324–331
  105. Nadir Y, Katz T, Sarig G, et al. Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor. Haematologica. 2005;90:1549–1556
  106. Nakasaki T, Wada H, Watanabe R, et al. Elevated tissue factor levels in leukemic cell homogenate. Clin Appl Thromb Hemost. 2000;6:14–17
  107. Lopez-Pedrera C, Jardi M, del Mar MM, et al. Tissue factor (TF) and urokinase plasminogen activator receptor (uPAR) and bleeding complications in leukemic patients. Thromb Haemost. 1997;77:62–70
  108. Tanaka M, Yamanishi H. The expression of tissue factor antigen and activity on the surface of leukemic cells. Leuk Res. 1993;17:103–111
  109. Bauer KA, Conway EM, Bach R, et al. Tissue factor gene expression in acute myeloblastic leukemia. Thromb Res. 1989;56:425–430
  110. Negaard HF, Iversen PO, Ostenstad B, et al. Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor. Thromb Haemost. 2008;99:1040–1048
  111. Semeraro N, Montemurro P, Giordano P, et al. Increased mononuclear cell tissue factor and type-2 plasminogen activator inhibitor and reduced plasma fibrinolytic capacity in children with lymphoma. Thromb Haemost. 1994;72:54–57
  112. Goldin-Lang P, Tran QV, Fichtner I, et al. Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep. 2008;20:123–128
  113. Rauch U, Antoniak S, Boots M, et al. Association of tissue-factor upregulation in squamous-cell carcinoma of the lung with increased tissue factor in circulating blood. Lancet Oncol. 2005;6:254
  114. Del Conde I, Bharwani LD, Dietzen DJ, et al. Microvesicle-associated tissue factor and Trousseau's syndrome. J Thromb Haemost. 2007;5:70–74
  115. Langer F, Spath B, Haubold K, et al. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation. Ann Hematol. 2008;
  116. Sawada M, Miyake S, Ohdama S, et al. Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. Br J Cancer. 1999;79:472–477
  117. Koomagi R, Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer. 1998;79:19–22
  118. Kageshita T, Funasaka Y, Ichihashi M, et al. Differential expression of tissue factor and tissue factor pathway inhibitor in metastatic melanoma lesions. Pigment Cell Res. 2002;15:212–216
  119. Uno K, Homma S, Satoh T, et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer. 2007;96:290–295
  120. Han LY, Landen CN, Kamat AA, et al. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol. 2006;24:755–761
  121. Zacharski LR, Memoli VA, Ornstein DL, et al. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst. 1993;85:1225–1230
  122. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007;13:2870–2875
  123. Haas SL, Jesnowski R, Steiner M, et al. Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J Gastroenterol. 2006;12:4843–4849
  124. Nitori N, Ino Y, Nakanishi Y, et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2005;11:2531–2539
  125. Kakkar AK, Lemoine NR, Scully MF, et al. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg. 1995;82:1101–1104
  126. Poon RT, Lau CP, Ho JW, et al. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res. 2003;9:5339–5345
  127. Kaushal V, Mukunyadzi P, Siegel ER, et al. Expression of tissue factor in prostate cancer correlates with malignant phenotype. Appl Immunohistochem Mol Morphol. 2008;16:1–6
  128. Babiker AA, Ekdahl KN, Nilsson B, et al. Prothrombotic effects of prostasomes isolated from prostatic cancer cell lines and seminal plasma. Semin Thromb Hemost. 2007;33:80–86
  129. Langer F, Chun FK, Amirkhosravi A, et al. Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers. Thromb Haemost. 2007;97:464–470
  130. Akashi T, Furuya Y, Ohta S, et al. Tissue factor expression and prognosis in patients with metastatic prostate cancer. Urology. 2003;62:1078–1082
  131. Ohta S, Wada H, Nakazaki T, et al. Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer. Anticancer Res. 2002;22:2991–2996
  132. Abdulkadir SA, Carvalhal GF, Kaleem Z, et al. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol. 2000;31:443–447
  133. Milsom C, Yu J, May L, et al. The role of tumour- and host-related tissue factor pools in oncogene-driven tumour progression. Thromb Res. 2007;120(Suppl. 2):S82–S91

PII: S1521-6926(08)00112-6

doi: 10.1016/j.beha.2008.12.008

Best Practice & Research Clinical Haematology
Volume 22, Issue 1 , Pages 71-83 , March 2009

Article Tools

* Image Usage & Resolution